10 November 2015 - The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).

For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm471934.htm